TY  - JOUR
AU  - Vasić, Marko
AU  - Loncar-Turukalo, Tatjana
AU  - Tasić, Tatjana
AU  - Matić, Marija
AU  - Glumac, Sofija
AU  - Bajić, Dragana
AU  - Popović, Branka
AU  - Japundžić-Žigon, Nina
PY  - 2019
UR  - https://smile.stomf.bg.ac.rs/handle/123456789/2469
AB  - Using comprehensive analysis of heart rate (HRV) and blood pressure (BPV) short-term variability we estimated the time course of changes of autonomic nervous system remodeling in two stages of doxorubicin-induced cardiomyopathy (DCM). We also investigated the level of gene expression of cardiac beta-1 (beta-1AR) and beta-2 (beta-2AR) adrenoceptors. Experiments were performed in adult male Wistar rats equipped with indwelling catheters for BP recording and blood withdrawal. A 15 mg/kg total cumulative dose of doxorubicin was injected i.p. to rats to induce DCM or saline for control (n = 18). Rats were assessed for general toxicity, cardiovascular hemodynamic and echocardiography before treatment (n = 6), 35 days (DOX35; n = 6) and 70 days (DOX70; n = 6) post-treatment. HRV was evaluated by spectral analysis, Poincare plots, sample and approximate entropy. Expression of beta-1AR and beta-2AR mRNA was evaluated by RT-qPCR. Doxorubicin-treated rats exhibited poor general condition and lower survival than saline-treated rats. In DOX35 rats, there were no echocardiography signs of decompensation, no increase in serum cardiac troponins, but there was an increase of HRV and decrease of HR complexity. In these rats typical microscopic signs of cardiotoxicity were seen along with over-expression of beta-1AR mRNA. 70 days post-treatment echocardiography revealed signs of decompensation and serum cardiac troponin T was increased. At this stage BPV decreased. In conclusion, HRV increase matches transient over expression of cardiac beta-1AR mRNA in compensate stage of DCM while decompensate stage of DCM is characterized by a decrease of BPV and no changes in beta-1AR and beta-2AR gene expression.
PB  - Academic Press Inc Elsevier Science, San Diego
T2  - Toxicology & Applied Pharmacology
T1  - Cardiovascular variability and beta-ARs gene expression at two stages of doxorubicin - Induced cardiomyopathy
VL  - 362
SP  - 43
EP  - 51
DO  - 10.1016/j.taap.2018.10.015
ER  - 

@article{
author = "Vasić, Marko and Loncar-Turukalo, Tatjana and Tasić, Tatjana and Matić, Marija and Glumac, Sofija and Bajić, Dragana and Popović, Branka and Japundžić-Žigon, Nina",
year = "2019",
abstract = "Using comprehensive analysis of heart rate (HRV) and blood pressure (BPV) short-term variability we estimated the time course of changes of autonomic nervous system remodeling in two stages of doxorubicin-induced cardiomyopathy (DCM). We also investigated the level of gene expression of cardiac beta-1 (beta-1AR) and beta-2 (beta-2AR) adrenoceptors. Experiments were performed in adult male Wistar rats equipped with indwelling catheters for BP recording and blood withdrawal. A 15 mg/kg total cumulative dose of doxorubicin was injected i.p. to rats to induce DCM or saline for control (n = 18). Rats were assessed for general toxicity, cardiovascular hemodynamic and echocardiography before treatment (n = 6), 35 days (DOX35; n = 6) and 70 days (DOX70; n = 6) post-treatment. HRV was evaluated by spectral analysis, Poincare plots, sample and approximate entropy. Expression of beta-1AR and beta-2AR mRNA was evaluated by RT-qPCR. Doxorubicin-treated rats exhibited poor general condition and lower survival than saline-treated rats. In DOX35 rats, there were no echocardiography signs of decompensation, no increase in serum cardiac troponins, but there was an increase of HRV and decrease of HR complexity. In these rats typical microscopic signs of cardiotoxicity were seen along with over-expression of beta-1AR mRNA. 70 days post-treatment echocardiography revealed signs of decompensation and serum cardiac troponin T was increased. At this stage BPV decreased. In conclusion, HRV increase matches transient over expression of cardiac beta-1AR mRNA in compensate stage of DCM while decompensate stage of DCM is characterized by a decrease of BPV and no changes in beta-1AR and beta-2AR gene expression.",
publisher = "Academic Press Inc Elsevier Science, San Diego",
journal = "Toxicology & Applied Pharmacology",
title = "Cardiovascular variability and beta-ARs gene expression at two stages of doxorubicin - Induced cardiomyopathy",
volume = "362",
pages = "43-51",
doi = "10.1016/j.taap.2018.10.015"
}

Vasić, M., Loncar-Turukalo, T., Tasić, T., Matić, M., Glumac, S., Bajić, D., Popović, B.,& Japundžić-Žigon, N.. (2019). Cardiovascular variability and beta-ARs gene expression at two stages of doxorubicin - Induced cardiomyopathy. in Toxicology & Applied Pharmacology
Academic Press Inc Elsevier Science, San Diego., 362, 43-51.
https://doi.org/10.1016/j.taap.2018.10.015

Vasić M, Loncar-Turukalo T, Tasić T, Matić M, Glumac S, Bajić D, Popović B, Japundžić-Žigon N. Cardiovascular variability and beta-ARs gene expression at two stages of doxorubicin - Induced cardiomyopathy. in Toxicology & Applied Pharmacology. 2019;362:43-51.
doi:10.1016/j.taap.2018.10.015 .

Vasić, Marko, Loncar-Turukalo, Tatjana, Tasić, Tatjana, Matić, Marija, Glumac, Sofija, Bajić, Dragana, Popović, Branka, Japundžić-Žigon, Nina, "Cardiovascular variability and beta-ARs gene expression at two stages of doxorubicin - Induced cardiomyopathy" in Toxicology & Applied Pharmacology, 362 (2019):43-51,
https://doi.org/10.1016/j.taap.2018.10.015 . .